Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all Quoted phrase not found: "Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C"
Page 1
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
Fernández I, Muñoz-Gómez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, Arias A, Prieto M, Castells L, Cuervas-Mons V, Hernández O, Crespo J, Calleja JL, Forns X, Londoño MC. Fernández I, et al. J Hepatol. 2017 Apr;66(4):718-723. doi: 10.1016/j.jhep.2016.12.020. Epub 2016 Dec 28. J Hepatol. 2017. PMID: 28039098
The aims of the study were to evaluate the efficacy and tolerability of DAAs in kidney transplant (KT) recipients. ...CONCLUSIONS: Antiviral therapy with DAAs was highly efficacious and safe in KT recipients. ...
The aims of the study were to evaluate the efficacy and tolerability of DAAs in kidney transplant (KT) recipi
Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation.
Cholongitas E, Pipili C, Papatheodoridis GV. Cholongitas E, et al. World J Hepatol. 2017 Feb 8;9(4):180-190. doi: 10.4254/wjh.v9.i4.180. World J Hepatol. 2017. PMID: 28217256 Free PMC article. Review.
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several cu …
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that u …
Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study.
Darema M, Cholongitas E, Filiopoulos V, Marinaki S, Pavlopoulou ID, Tsoubou I, Boletis JN, Papatheodoridis GV. Darema M, et al. Ann Gastroenterol. 2020 May-Jun;33(3):285-292. doi: 10.20524/aog.2020.0481. Epub 2020 Apr 14. Ann Gastroenterol. 2020. PMID: 32382232 Free PMC article.
BACKGROUND: The recent interferon-free direct-acting antiviral (DAA) regimens have very good safety and efficacy profiles and are highly recommended for kidney transplant (KT) recipients with chronic hepatitis C
BACKGROUND: The recent interferon-free direct-acting antiviral (DAA) regimens have very good safety and efficacy
Changing the face of hepatitis C management - the design and development of sofosbuvir.
Noell BC, Besur SV, deLemos AS. Noell BC, et al. Drug Des Devel Ther. 2015 Apr 24;9:2367-74. doi: 10.2147/DDDT.S65255. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25987834 Free PMC article. Review.
The availability of direct-acting antiviral (DAA) therapy has launched a new era in the management of chronic hepatitis C. Sofosbuvir, a uridine nucleotide analog that inhibits the hepatitis C RNA-dependent RNA polymerase, is the b …
The availability of direct-acting antiviral (DAA) therapy has launched a new era in the management of chronic hepati